Summit Therapeutics Inc. (SMMT) stock
SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.50−0.17 (-1.59%)
Close on Nov 18, 2026Market cap $8.38BP/E –Yield –
Summit Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Summit Therapeutics's price to book ratio was 20.9× on Nov 11, 2026, against 69.3× a year earlier. Over the last 5 years it ranged from 1.2× to 171.5×, with a median of 20.9×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 20.9× | −46.8 |
| 2025 | Dec 31, 2025 | 67.7× | +37.7 |
| 2024 | Dec 31, 2024 | 30.0× | +11.7 |
| 2023 | Dec 29, 2023 | 18.3× | +11.9 |
| 2022 | Dec 30, 2022 | 6.4× | +3.9 |
| 2021 | Dec 31, 2021 | 2.6× | +1.2 |
| 2020 | Dec 31, 2020 | 1.4× | +0.9 |
| 2019 | Dec 31, 2019 | 0.5× | – |
See a number that looks wrong?